Addressing the unmet need in NSCLC progression with advances in second-line therapeutics
{{output}}
Lung cancer is the leading cause of cancer mortality globally, with non-small cell lung cancer (NSCLC) accounting for 85% of cases. Despite advancements in first-line treatments such as immunotherapy and targeted therapies, resistance to these treatments is co... ...